Last reviewed · How we verify
RIF
RIF is a rifampicin-based antimicrobial agent used in pediatric leukemia supportive care to prevent or treat infections.
RIF is a rifampicin-based antimicrobial agent used in pediatric leukemia supportive care to prevent or treat infections. Used for Infection prophylaxis and treatment in pediatric leukemia patients.
At a glance
| Generic name | RIF |
|---|---|
| Also known as | Realgar-Indigo naturalis formula, rifampicin |
| Sponsor | South China Children's Leukemia Group |
| Drug class | Rifamycin antibiotic |
| Target | Bacterial RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Oncology (supportive care) / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Rifampicin is a broad-spectrum antibiotic that inhibits bacterial RNA polymerase, preventing transcription and translation in susceptible microorganisms. In the context of pediatric leukemia, it is typically used as part of infection prophylaxis or treatment regimens in immunocompromised patients undergoing chemotherapy.
Approved indications
- Infection prophylaxis and treatment in pediatric leukemia patients
Common side effects
- Hepatotoxicity
- Drug interactions
- Gastrointestinal disturbance
- Discoloration of body fluids
Key clinical trials
- Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) (PHASE2)
- Shortened Regimen for Drug-susceptible TB in Children (PHASE3)
- Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis (PHASE1)
- An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM (PHASE3)
- Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (PHASE2)
- AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT (PHASE2)
- Effect of Acupuncture on IVF Pregnancy Outcomes for Women With RIF (NA)
- A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RIF CI brief — competitive landscape report
- RIF updates RSS · CI watch RSS
- South China Children's Leukemia Group portfolio CI